Cheng Wang

发表

Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants

R. Chowdhury, Bríain ó. Hartaigh, H. Yuce, 2019, Journal of medical economics.

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds

Bríain ó. Hartaigh, A. Spyropoulos, C. Lipkin, 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries

A. Kansal, P. Gandhi, K. Deger, 2018, Current medical research and opinion.

Comparison of healthcare costs among patients with non‐valvular atrial fibrillation treated with warfarin who switched to a novel oral anticoagulant

Bríain ó. Hartaigh, A. Gilligan, Xue Song, 2020 .

Healthcare Resource Utilization among Non-Valvular Atrial Fibrillation Patients Who Switched from Warfarin to a Novel Oral Anti-Coagulant

Bríain ó. Hartaigh, A. Gilligan, Xue Song, 2019, Journal of Cardiology and Cardiovascular Sciences.

Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population

V. Willey, R. Jain, H. Tan, 2018, BMJ Open.

Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants

David M. Smith, A. Gilligan, Xue Song, 2018, Current medical research and opinion.

All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin

David M. Smith, A. Gilligan, P. Gandhi, 2017, American Journal of Cardiovascular Drugs.

Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States.

S. Sander, J. Swindle, T. Bancroft, 2016, Clinical therapeutics.

Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin

David M. Smith, A. Gilligan, P. Gandhi, 2019, Expert review of pharmacoeconomics & outcomes research.

Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin

David M. Smith, A. Gilligan, Xue Song, 2018, Expert review of pharmacoeconomics & outcomes research.

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin

S. Annavarapu, P. Gandhi, S. Sander, 2017, Health and Quality of Life Outcomes.

Healthcare Resource Utilization for Oral Anticoagulant Reversal Therapies in Non-Valvular Atrial Fibrillation/Venous Thromboembolism Patients

Bríain ó. Hartaigh, S. Robinson, A. Spyropoulos, 2022, Cardiology research.

Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation.

S. Annavarapu, P. Gandhi, S. Sander, 2018, Journal of comparative effectiveness research.

Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States

R. Jain, H. Tan, S. Sander, 2018, Journal of managed care & specialty pharmacy.

Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants

David M. Smith, A. Gilligan, Xue Song, 2018, Current medical research and opinion.